Optogenetics, recognized by the 2026 medicine Nobel, makes cells respond to light, including eye cells that normally relay ...
Chico Enterprise-Record on MSN
Enloe Health to receive $9M to expand cell, gene therapy access
Enloe Health announced Monday that was selected to receive a $9 million grant from the California Institute for Regenerative ...
A Bengaluru infant diagnosed with Spinal Muscular Atrophy at just five weeks old has successfully received gene replacement ...
The FDA has approved 'Otarmeni', the first gene therapy for congenital hearing loss (DFNB9) caused by OTOF gene mutations.It ...
Dublin, Oct. 12, 2026 (GLOBE NEWSWIRE) -- "Preclinical Imaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
Aged beagle data hint at lower biological age and preliminary muscle changes with SIRT6c treatment, although key readouts ...
A gene therapy based on Nobel prize-winning science has partially restored sight in some blind patients, with a clinical ...
The underlying field was recognized this week when the 2026 Nobel Prize in Physiology or Medicine went to Karl Deisseroth, MD ...
At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews sura-vec, 4D-150 and ixo-vec, 3 nAMD gene therapies in phase 3 with ...
Optogenetic therapy, based on Nobel prize-winning science, involves turning nerve cells on and off using light ...
The U.S. Food and Drug Administration today approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as ...
Record global approvals, CRISPR breakthroughs, and expanding clinical and commercial activity are accelerating demand for cell and gene therapy tools and reagents.Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results